ABPI welcomes first women's health strategy for England

The Government has today published the first women's health strategy for England, to tackle the gender health gap. 

Tackling the longstanding research and data gaps which exist in women’s health has been a longstanding priority for ABPI and our members, and we are pleased to see this strategy seek to address them. Jennifer Harris, ABPI Director of Research Policy

In response, Jennifer Harris, Director of Research Policy at the ABPI said:

“Only through increased research involving women - and about conditions affecting women – can we bring improved treatments to all women.  Pharmaceutical companies are stepping up their work in this area to make sure that clinical trials are more inclusive to underserved groups, including women of all ages.  

“Tackling the longstanding research and data gaps which exist in women’s health has been a longstanding priority for ABPI and our members, and we are pleased to see this strategy seek to address them.”

Background information

The ABPI gave evidence to the consultation on the UK Government’s Women’s Health Strategy, highlighting the current lack of data in this area and recommended that like the FDA, UK regulatory authorities and funders should collect data on clinical trial participation to establish a baseline on which to build.

The ABPI contributed to the development of a vision to improve the lives of women while they are pregnant, led by Birmingham Health Partners.

ABPI members are also taking action to improve treatment options for pregnant women through international initiatives, like IMI Conception and Transcelerate

TAGS
  • Clinical research

Last modified: 20 July 2022

Last reviewed: 20 July 2022

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.